Kosmos is a POCUS system that offers continuous-wave Doppler capability, a feature with important applications in cardiology. Also, Kosmos is the only product of its size and in its category to meet Health Insurance Portability and Accountability Act (HIPAA) requirements for data collection, storage, and transmission, EchoNous said.
EchoNous reported it received the funding from a single investor, Kennedy Lewis, and that it builds on the support it receives from KKR, which has been its principal investor since 2015.
Kosmos was cleared by the U.S. Food and Drug Administration in March 2020.
Copyright © 2021 AuntMinnieEurope.com